第 1 到 19 筆結果,共 19 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2023 | Genomic and Transcriptomic Landscape of an Oral Squamous Cell Carcinoma Mouse Model for Immunotherapy | Lee, Yi-Mei; Hsu, Chia-Lang; Chen, Yu-Hsin; DA-LIANG OU ; CHIUN HSU ; Tan, Ching-Ting | Cancer immunology research | |||
2 | 2022 | Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma | YU-YUN SHAO ; Chen, Pai-Sheng; LIANG-IN LIN ; Lee, Bin-Shyun; Ling, Andrew; ANN-LII CHENG ; CHIUN HSU ; DA-LIANG OU | British journal of cancer | 10 | 10 | |
3 | 2022 | Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer | Hsieh, Ching-Hung; Jian, Cheng-Zhe; LIANG-IN LIN ; Low, Guan-Sian; Ou, Ping-Yun; CHIUN HSU ; DA-LIANG OU | Cancers | 24 | 17 | |
4 | 2021 | Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma | CHIA-LANG HSU ; DA-LIANG OU ; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG ; YUNG-MING JENG ; CHIUN HSU | Liver Cancer | 47 | 47 | |
5 | 2021 | Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages | DA-LIANG OU ; Chen C.-W.; CHIA-LANG HSU ; Chung C.-H.; Feng Z.-R.; Lee B.-S.; ANN-LII CHENG ; Yang M.-H.; CHIUN HSU | Journal for ImmunoTherapy of Cancer | 68 | 44 | |
6 | 2019 | Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma | DA-LIANG OU ; Lin, Yu-Yang; CHIA-LANG HSU ; Lin, Yin-Yao; Chen, Chia-Wei; Yu, Jhang-Sian; SHI-CHUEN MIAW ; PING-NING HSU ; ANN-LII CHENG ; CHIUN HSU | Liver cancer | 24 | 21 | |
7 | 2018 | Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy | Lin Y.-Y.; CHING-TING TAN ; Chen C.-W.; DA-LIANG OU ; ANN-LII CHENG ; CHIUN HSU | Seminars in Liver Disease | 62 | 53 | |
8 | 2017 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy | YU-YUN SHAO ; BANG-BIN CHEN ; DA-LIANG OU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; Wang, M. J.; ANN-LII CHENG ; CHIUN HSU | Alimentary Pharmacology and Therapeutics | 10 | 8 | |
9 | 2017 | Simultaneous visualization of the subfemtomolar expression of microRNA and microRNA target gene using HILO microscopy | Lin Y.-Z.; DA-LIANG OU ; Chang H.-Y.; Lin W.-Y.; CHIUN HSU ; Chang P.-L. | Chemical Science | 14 | 13 | |
10 | 2016 | Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression | CHIUN HSU ; LIANG-IN LIN ; Cheng, Yu-Che; Feng, Zi-Rui; YU-YUN SHAO ; ANN-LII CHENG ; DA-LIANG OU | Clinical Cancer Research | 43 | 41 | |
11 | 2015 | Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma | DA-LIANG OU ; Shyue S.-K.; LIANG-IN LIN ; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S.; CHIUN HSU ; ANN-LII CHENG | Oncotarget | 12 | 9 | |
12 | 2014 | Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma | DA-LIANG OU ; Chang C.-J.; YUNG-MING JENG ; Lin Y.-J.; ZHONG-ZHE LIN ; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; CHIUN HSU ; ANN-LII CHENG | Journal of Gastroenterology and Hepatology (Australia) | 11 | 13 | |
13 | 2014 | H3K9 histone methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis | Wu P.-C.; Lu J.-W.; Yang J.-Y.; Lin I.-H.; DA-LIANG OU ; Lin Y.-H.; Chou K.-H.; Huang W.-F.; Wang W.-P.; Huang Y.-L.; CHIUN HSU ; LIANG-IN LIN ; Lin Y.-M.; James Shen C.-K.; Tzeng T.-Y. | Cancer Research | 54 | 53 | |
14 | 2014 | Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivin | DA-LIANG OU ; Lee B.-S.; LIANG-IN LIN ; Liou J.-Y.; Liao S.-C.; CHIUN HSU ; ANN-LII CHENG | Molecular Cancer | 41 | 33 | |
15 | 2013 | Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway | DA-LIANG OU ; Lee B.-S.; Chang Y.-C.; LIANG-IN LIN ; Liou J.-Y.; CHIUN HSU ; ANN-LII CHENG | PLoS ONE | 10 | 11 | |
16 | 2013 | Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma | Ying-Chun Shen ; DA-LIANG OU ; CHIUN HSU ; Lin K.-L.; Chang C.-Y.; CHING-YU LIN ; Liu S.-H.; ANN-LII CHENG | British Journal of Cancer | 155 | 146 | |
17 | 2012 | Comparative microRNA detection from precursor-microRNA-transfected hepatocellular carcinoma cells by capillary electrophoresis with dual-color laser-induced fluorescence | Yang T.-H.; DA-LIANG OU ; CHIUN HSU ; Huang S.-H.; Chang P.-L. | Electrophoresis | 17 | 17 | |
18 | 2010 | Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells | DA-LIANG OU ; Ying-Chun Shen ; SUNG-LIANG YU ; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; LIANG-IN LIN ; CHIUN HSU ; ANN-LII CHENG | Cancer Research | 70 | 69 | |
19 | 2009 | Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma | DA-LIANG OU ; Ying-Chun Shen ; JA-DER LIANG ; Liou J.-Y.; SUNG-LIANG YU ; Fan H.-H.; Wang D.-S.; YEN-SHEN LU ; CHIUN HSU ; ANN-LII CHENG | Clinical Cancer Research | 32 | 34 |